利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

117 条记录 (耗时 0.044 秒)

    Console box
    2.
    发明授权
    Console box 失效
    控制台

    公开(公告)号：US07004527B2

    公开(公告)日：2006-02-28

    申请号：US11057782

    申请日：2005-02-15

    申请人： Kenji Niwa ,  Akira Yamauchi ,  Shigeru Yabuya ,  Etsuo Ozawa ,  Takahiko Sato ,  Hiroki Imamura ,  Yuji Shimizu

    发明人： Kenji Niwa ,  Akira Yamauchi ,  Shigeru Yabuya ,  Etsuo Ozawa ,  Takahiko Sato ,  Hiroki Imamura ,  Yuji Shimizu

    IPC分类号： B60R7/04

    CPC分类号： B60R7/04 ,  B60N2/773 ,  B60N2/793

    摘要： A console box of the present invention has a box main body, a pair of sidewalls, and an armrest. The box main body is located between the sidewalls, and the armrest is located above the box main body. Each sidewall has a guide groove extending in the moving direction of the vehicle. The armrest has a pair of engaging pins. Each engaging pin is engaged with and slides along one of the guide grooves. Thus, the armrest smoothly slides along the moving direction of the vehicle.

    摘要翻译： 本发明的控制箱具有盒主体，一对侧壁和扶手。 箱主体位于侧壁之间，扶手位于箱体主体的上方。 每个侧壁具有在车辆的移动方向上延伸的引导槽。 扶手有一对接合销。 每个接合销与其中一个引导槽接合并滑动。 因此，扶手平稳地沿着车辆的移动方向滑动。

    MONOCLONAL ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST MMP13
    8.
    发明申请
    MONOCLONAL ANTIBODY HAVING NEUTRALIZING ACTIVITY AGAINST MMP13 失效
    具有对MMP13的中和活性的单克隆抗体

    公开(公告)号：US20100330092A1

    公开(公告)日：2010-12-30

    申请号：US12668201

    申请日：2008-07-08

    申请人： Shoichi Naito ,  Junji Onoda ,  Akira Yamauchi ,  Yoshito Numata ,  Junji Kishono

    发明人： Shoichi Naito ,  Junji Onoda ,  Akira Yamauchi ,  Yoshito Numata ,  Junji Kishono

    IPC分类号： A61K39/395 ,  C07K16/40 ,  C12N5/16 ,  G01N33/573 ,  C12N9/99

    CPC分类号： G01N33/573 ,  C07K16/40 ,  C07K2317/76 ,  G01N2333/8146

    摘要： A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.

    摘要翻译： 提供了与MMP13特异性反应的中和单克隆抗体，中和MMP13的酶活性的方法和各自使用该抗体的免疫学测定方法，以及含有该抗体的诊断剂和药物组合物。 迄今为止已经获得了MMP13的各种抗体，但是尚未获得具有针对MMP13的中和活性的抗体。 本发明人深入研究了结果，发现了对MMP13具有特异性的中和抗体，从而完成了本发明。

    Novel modified galectin 9 proteins and use thereof
    9.
    发明申请
    Novel modified galectin 9 proteins and use thereof 有权
    新型改良的半乳凝素9蛋白及其用途

    公开(公告)号：US20100203628A1

    公开(公告)日：2010-08-12

    申请号：US11547091

    申请日：2005-03-29

    申请人： Nozomu Nishi ,  Mitsuomi Hirashima ,  Akira Yamauchi ,  Aiko Ito

    发明人： Nozomu Nishi ,  Mitsuomi Hirashima ,  Akira Yamauchi ,  Aiko Ito

    IPC分类号： C12N5/00 ,  C07K14/435 ,  C12N15/12 ,  C12N15/63

    CPC分类号： C07K14/4726 ,  A61K38/00 ,  A61K48/00 ,  Y02A50/402 ,  Y02A50/406 ,  Y02A50/411 ,  Y02A50/463 ,  Y02A50/471 ,  Y02A50/475 ,  Y02A50/48

    摘要： It is suggested that recombinant galectin 9 (rGal 9), produced in host Escherichia coli, exhibits an immune system-mediated action and a direct action on tumor cells (i.e., activity of inducing the intercellular adhesion and apoptosis of the tumor cells), thereby potent in inducing the inhibition of cancer metastasis and reduction. Moreover, the rGal 9 exerts no efficacy on non-activated lymphocytes but can induce apoptosis in activated T cells, in particular, CD4-positive T cells causing an excessive immune response. The rGal 9 has a further potent apoptosis-inducing property on synovial cells participating in joint deformation in rheumatism, etc. In the rGal 9, however, a link domain linking two CRDs is highly susceptible to protease and, therefore, is very easily digestible with the enzyme, thereby losing the above activities. Thus, there is a need for a more stabilized molecule in view of further studies. Modification of the link domain linking two CRDs in galectin 9 provides a modified molecule having an elevated activity without any undesirable effects on the above activities.

    摘要翻译： 建议在宿主大肠杆菌中产生的重组半乳凝素9（rGal 9）表现出免疫系统介导的作用和对肿瘤细胞的直接作用（即，诱导肿瘤细胞的细胞间粘附和凋亡的活性），由此 有效诱导癌症转移和还原的抑​​制。 此外，rGal9对非活化淋巴细胞没有效力，但可以诱导活化的T细胞，特别是导致过度免疫应答的CD4阳性T细胞的细胞凋亡。 rGal9对参与风湿病关节变形的滑膜细胞具有更强的细胞凋亡诱导性质。然而，在rGal9中，连接两个CRD的连接域对蛋白酶非常敏感，因此很容易被消化 该酶，从而失去上述活性。 因此，鉴于进一步研究，需要更稳定的分子。 连接半乳凝素9中两个CRD的连接结构域的修饰提供了具有升高活性的修饰分子，而对上述活性没有任何不良影响。